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A review of published evidence of superior efficacy of a
particular antidepressant in major depressive disorder may
assist clinicians in making considered treatment choices.
To identify such candidates, an international group of
experts met to assess published evidence (identified
through searches in Medline and Embase databases and
discussions with experts in the field) from randomized,
controlled trials and meta-analyses comparing two
antidepressants under conditions of fair comparison.
Criteria were defined to judge the strength of evidence.
Two pivotal studies in moderate-to-severe major
depressive disorder that demonstrate superiority on the
primary efficacy measure, or alternatively one pivotal study
supported by consistent results from meta-analyses, was
considered to constitute evidence for definite superiority.
Three antidepressants met these criteria: clomipramine,
venlafaxine, and escitalopram. Three antidepressants were
found to have probable superiority: milnacipran, duloxetine,
and mirtazapine. Only escitalopram was found to have
definite superiority in the treatment of severe depression;
probable superiority was identified for venlafaxine and
possible superiority for milnacipran and clomipramine. This
review of published data found evidence that only a very
few antidepressants are shown to be more effective than
others. Int Clin Psychopharmacol 22:323–329 c 2007
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Introduction
A group of experts met to discuss the data providing
evidence for the potential superior efficacy of one
antidepressant compared with others.
A preliminary review of the literature was conducted to
identify possible candidate antidepressants with some
evidence of superiority in clinical studies. The decision
was taken to rely on evidence from published randomized
controlled trials (RCT) in major depressive disorder
(MDD) or the equivalent in which two antidepressants
were compared with each other. Studies were accepted,
whether or not placebo controlled, providing that
recognized effective doses (as reflected in the data
sheets of each antidepressant) were used for both the
candidate and comparator antidepressants. Unpublished
data, when available, were taken into account but were
accorded a lower level of evidence. The search for
relevant studies was based on a search of Medline and
Embase databases, a manual search of bibliographies of
published papers and a discussion with experts in the
field.
Particular attention was paid to adherence to the
conditions of fair comparison, which were regarded as
important. An example of exclusion by this criterion is the
study that reported that sertraline was superior to
desipramine in obsessive compulsive disorder concurrent
with MDD (Hoehn-Saric et al., 2000). This study did not
meet the criterion of fair comparison as only selective
serotonin reuptake inhibitors (SSRIs) have been shown
to be effective in obsessive compulsive disorder and the
result could not therefore be accepted as showing
superiority for sertraline in MDD.
Several factors were taken into account. These included:
(a) The validity of the outcome variable, such as a
change in the rating scale score,
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(b) The usefulness of clinical measures, such as those of
response and remission,
(c) Methods of statistical analysis,
(d) Speed of onset of action, and accordingly, time course
of response,
(e) Usefulness of combining data as compared with
meta-analyses,
(f) Types and subgroups of patients, particularly severely
depressed patients.
Criteria used to judge the strength of
evidence
The evidence of superiority for an antidepressant was
categorized:
Class A evidence
The most convincing level of evidence was accorded to
data from an RCT that on the primary efficacy analysis
under conditions of fair comparison showed a significant
advantage in moderate or severe MDD of one anti-
depressant over another at approved doses. A single
positive study demonstrating a significant advantage of
one antidepressant over another in a head-to-head
comparison was taken to indicate probable superiority.
Two positive RCTs showing significant superiority in
efficacy on the primary efficacy measure were taken to
show clear-cut or definite superiority. The evidence is
more persuasive if the data come from RCTs of a
reasonable size compatible with those needed to find a
difference from placebo, as very small studies are prone to
problems with replication. Class A evidence that finds a
treatment difference in individual studies of the same
order as the drug placebo difference used to establish
efficacy in licensing is by definition clinically relevant.
Class B evidence
The demonstration of the superiority of one antidepres-
sant over other antidepressants on the primary efficacy
measure in a meta-analysis of head-to-head comparisons
in RCTs in moderate-to-severe MDD at approved doses
and under conditions of fair comparison was categorized
as Class B evidence. Meta-analyses of studies are almost
always, by definition, carried out post hoc so that the
evidence could be regarded as hypothesis generating
rather than confirmatory.
Meta-analyses are subject to potential imbalances in
populations studied, differing severities, and differing
methodology employed in each study. Moreover, there is
the risk that a significant difference reported in a large
meta-analysis might reflect a small or very small
difference between the treatments, which may not be
clinically relevant. For these reasons, the evidence from
meta-analyses is regarded as less strong than evidence
from well-designed, individual controlled studies. The
analysis of subgroup efficacy, for example responders or
remitters, reported in some meta-analyses, although
interesting, is less convincing than the conventional
change from baseline on the pivotal efficacy measure.
It is possible that positive results from meta-analyses
might be affected by including only the results from
positive studies. Contradictory results from more com-
prehensive meta-analyses including more studies would
weaken the claim for superiority. Consistent evidence of
superiority from more than one meta-analysis, although
the same datasets are usually included, was taken to
provide evidence of probable superior efficacy.
Evidence of superiority from one Class A study showing
superiority allied with consistent evidence of superiority
from meta-analysis was taken as definite evidence of
superior efficacy.
Class C evidence
Evidence from uncontrolled studies or from RCTs that
did not meet all the criteria for Class A evidence was
designated Class C evidence. Class C evidence is
regarded only as hypothesis generating, providing evi-
dence at most of possible superiority. Open studies and
case reports were discounted.
The experts considered the available evidence indicating
that an antidepressant might possess superior efficacy
and identified whether the evidence met criteria for
possible, probable or definite superior efficacy. This
review of antidepressants with superior efficacy may
assist clinicians in making considered treatment choices.
Superior antidepressant candidates
The candidate antidepressants identified on the basis of
published claims that they might have advantage over
other antidepressants in terms of efficacy were clomipra-
mine, duloxetine, escitalopram, milnacipran, mirtazapine,
and venlafaxine.
Clomipramine
In two randomized controlled studies, the Danish
University Antidepressant Group DUAG (1986, 1990)
reported a significant advantage for clomipramine
(150mg) over the SSRIs citalopram (40mg) and parox-
etine (30mg). Clomipramine was also superior to the
reversible monoamine oxidase inhibitor (RIMA) moclo-
bemide but the dose of moclobemide might have been
too low for the study to meet conditions of fair
comparison (DUAG, 1993). Clomipramine treatment
was associated with a significantly greater reduction in
Hamilton Depression Rating Scale (HAMD) score than
either of the SSRIs. These two studies provide reason-
able class A evidence that clomipramine has definite
superior efficacy as an antidepressant.
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The studies, however, have design flaws, which to some
degree compromise this evidence. The diagnostic criteria
varied between studies so that it is difficult to generalize
to other populations. It has been argued that the HAMD
measure may have favoured the much more sedative
clomipramine and possibly compromised the blindness.
When clusters of HAMD items were analysed separately
in the studies, significant difference was clearly most
evident for sleep disturbance, which accounted for nearly
half of the total difference (DUAG, 1986). It can be
argued that improvement in sleep is an important part of
the clinical response to an antidepressant. Inpatient
status may also convey an indirect advantage for the less
well tolerated tricyclic antidepressants (TCAs), as nur-
sing support facilitates both adherence and management
of some side effects (i.e. constipation or orthostatic
hypotension). Nevertheless, despite these issues, the
presence of at least two positive studies constitutes Class
A evidence of the superiority of clomipramine in treating
depression.
Clomipramine has definite evidence of superiority
as an antidepressant
The extrapolation of the results from studies with
clomipramine to the efficacy of other TCAs as suggested
by Anderson and Tomenson (1994) does not appear to be
justified. Meta-analyses of data for imipramine or
amitriptyline have not produced evidence of superiority,
at least at the doses used in RCTs, which tended to be
low. A subsequent report by Anderson (1998), which
limited the meta-analysis to inpatient studies, did report
a significant difference favouring TCAs over SSRIs, with a
secondary analysis indicating that the entire advantage
was accounted for by the studies utilizing the tertiary
amine TCAs (i.e. amitriptyline, clomipramine, and
imipramine). As the secondary amine TCAs and mapro-
tiline are generally considered to be predominantly
noradrenaline reuptake inhibitors, these findings are
often viewed as supporting the notion that antidepres-
sants with ‘dual effects’ might convey stronger anti-
depressant effects. Moreover, there is a suggestion from a
meta-analysis of imipramine data, taken from some of the
placebo-controlled studies submitted to the licensing
authorities in which imipramine was used as a comparator,
that higher doses of imipramine may be more effective
(Storosum et al., 2001).
Venlafaxine
Two RCTs provide Class A evidence of definite superi-
ority. Venlafaxine in a daily dosage of 200mg was found to
be significantly more effective on the primary outcome
measure (HAMD) than fluoxetine 40mg in hospitalized
MDD patients with severe depression, as reflected by a
HAMD score of 29 or more at baseline (Clerc et al., 1994).
The advantage on the primary measure was supported by
advantages for venlafaxine over fluoxetine seen on the
secondary measures. De Nayer et al. (2002) reported a
significantly greater response on venlafaxine 75–150mg
compared with fluoxetine 20–40mg over a 12-week
period in 120 depressed outpatients with high levels of
concomitant anxiety on both the HAMD and Montgom-
ery–Asberg Depression Rating Scale (MADRS). The
failure to use any recognized diagnostic criteria or to
exclude concomitant generalized anxiety disorder or
panic disorder is a potential bias as venlafaxine, but not
fluoxetine, is licensed for the treatment of generalized
anxiety disorder and panic disorder. This raises questions
as to whether the study meets criteria for a fair
comparison. As anxiety is recognized to be part of
depression, the study, however, provides some evidence
of the superiority of venlafaxine in the treatment of
depression. A study in resistant depression showed
venlafaxine to be superior to paroxetine but as resistance
was mostly to SSRIs and not to SNRIs, the study does not
meet the criterion of a fair comparison (Poirier and Boyer,
1999). Resistant depression is in any case not quite the
same as nonresistant depression. In a further study,
venlafaxine was reported to be superior to fluoxetine
(Dierick et al., 2006) but in this study, the dose in
nonresponders was only allowed to be raised with
venlafaxine which compromises the conditions of fair
comparison.
The results of numerous meta-analyses of the efficacy
data for venlafaxine compared with fluoxetine (Cipriani
et al., 2005), a mixture of several SSRIs (Stahl et al., 2002),
and to all antidepressants used in comparator studies,
support the conclusion that venlafaxine is a superior
antidepressant. These large meta-analyses have mainly
focused on the secondary measure of remission (Thase
et al., 2001; Smith et al., 2002; Thase, 2004) but also
provide evidence of superiority over comparators on the
primary measure of change from baseline on the HAMD,
at least in some of the analyses.
The conclusion that venlafaxine has definite superior
efficacy as an antidepressant is supported by Class A
evidence from the study of Clerc et al. (1994) using a dose
of 200mg/day and the study of De Nayer et al. (2002) at
the lower dose of 75–15mg and by consistent Class B
evidence from several meta-analyses. This conclusion
holds largely for the higher doses of venlafaxine used
in the studies and not for the lower daily dosages of
75–150mg (Thase et al., 2001).
Milnacipran
The superiority of milnacipran 100mg/day was reported in
a study that compared milnacipran with the SSRI
fluvoxamine 200mg/day (Clerc et al., 2001). Milnacipran
was significantly more effective measured in the change
from baseline on the pivotal MADRS at the 6-week end
point. The superiority of milnacipran 100mg/day com-
pared with fluoxetine 20mg/day was not shown at the
Superior antidepressants Montgomery et al. 325
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
12-week end point in a study by Guelfi et al. (1998); only
a post-hoc analysis showed a significant advantage at 4
weeks on the MADRS. As the superiority was not sustained
at end point, the evidence from this study is discounted.
Class A evidence from a single study (Clerc et al., 2001)
supports the probable superiority of milnacipran.
The meta-analysis carried out by Lopez-Ibor et al. (1996)
reported significantly higher responder rates on milnaci-
pran 100mg day (64%) than with the SSRIs fluoxetine
and fluvoxamine (50%). This advantage was apparently
driven substantially by the positive results in patients
with more severe depression. The 6-week data was used
as the end point in this analysis rather than the 12-week
end point in which superiority was not observed in the
study of Guelfi et al. (1998) and the strength of the
evidence is therefore less secure. A recent meta-analysis
(Papakostas and Fava, 2007), which included all pub-
lished studies including a large study mainly in patients
with mild-to-moderate depression (Sechter et al., 2004),
did not find evidence of superiority for milnacipran. The
results from the meta-analyses are therefore inconsistent
and evidence of superiority is based on the single positive
study of Clerc et al. (2001).
The data indicate the probable superiority of milnacipran
but there are insufficient data to support a conclusion of
definite superiority.
Duloxetine
Duloxetine in a dose of 80mg/day was reported to be
superior to paroxetine 20mg at the 8-week end point
measured on the change from baseline in the primary
measure, the HAMD. In this study, paroxetine was not
significantly different from placebo (Goldstein et al.,
2004). The effect was identified using the mixed model
repeated measures analytical approach, but not using the
standard last observation carried forward analysis.
A meta-analysis, as yet unpublished, is claimed to report
a significant 5% advantage for duloxetine compared with
its comparators when mild depression is excluded
(Thase, personal communication). Insufficient numbers
of patients with severe depression were included in these
studies to assess relative efficacy of duloxetine in severe
depression (EMEA EPAR on duloxetine, 2005).
Duloxetine (80mg) is considered to have probable super-
iority based on Class A evidence from one study, but the data
are not sufficiently clear-cut to indicate definite superiority.
The evidence of superiority applies only to doses of
80mg/day and not to the commonly used dose of 60mg/day.
Mirtazapine
Mirtazapine in a dose of 24–72mg was shown to have a
significantly better response compared with trazodone
150–450mg on the primary efficacy measure, the HAMD,
in hospitalized patients with moderate or severe depres-
sion with an entry score of 18 or more on the HAMD
(Van Moffaert et al., 1995).
This finding was not replicated in subsequent studies
(Benkert et al., 2006) or in meta-analysis (Montgomery
et al., 2002; Blier, 2003), which showed a consistent early
response rather than a clear superiority for mirtaza-
pine at end point. This early response was observed even
when the sleep items of the HAMD were excluded
which shows that this early response is not exclusively
dependent on the sedative effect of mirtazapine.
Mirtazapine is considered from the evidence of a single
study to have probable superiority as an antidepressant.
Escitalopram
Two separate studies have shown the superiority of 20mg
escitalopram compared with 40mg citalopram (Moore
et al., 2005) and 40mg paroxetine (Boulenger et al., 2006)
in conditions of fair comparison in 8-week randomized
controlled comparator studies in patients with severe
MDD. The significant superiority was observed on the
pivotal primary measure MADRS and on secondary
measures. This constitutes Class A evidence of definite
superiority.
Meta-analyses of the comparator studies have been able
to show a significant advantage for escitalopram compared
with citalopram (Gorman et al., 2002; Auquier et al., 2003;
Lepola et al., 2004), and all comparator antidepressants
tested (Kennedy et al., 2006). The individual studies and
the meta-analysis of all studies show the superiority of
escitalopram. Superiority is seen most clearly in the
severely depressed population (Lam and Andersen,
2006).
The superiority of escitalopram in treating depression is
clear cut and definite and is based on Class A evidence
from two studies and supported as well by consistent
results from meta-analyses.
Superiority in severe depression
The hospitalized patients included in the DUAG studies,
on which the conclusion of superior efficacy of clomipra-
mine in MDD is based, were in retrospect not particularly
severely ill, with minimum entry scores on the HAMD 17
of 18, which is barely in the moderate range and the mean
total HAMD scores on entry appear to be too low to
justify the claim for efficacy in severe depression. No
pooled analysis of these studies is available to give a
subanalysis of the data in moderate and severe patient
subgroups. The lack of an adequate prospective defini-
tion of severity on a severity scale weakens the evidence
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of the superiority of clomipramine in severe depression to
the level in which it can only be considered possible.
The superior efficacy of venlafaxine in severe depression
is based on the single positive comparator study in
hospitalized severe MDD (Clerc et al., 1994) and on a
meta-analysis of data from comparator studies with a
higher level of severity. The entry scores are variable
defined as more than 20 on the HAMD or more than 25
on the MADRS (Stahl et al., 2002). Class A evidence of
definite superior efficacy in patients with severe depres-
sion is therefore available from a single study and is
supported by some positive results from a meta-analysis
Class B data from meta-analysis of studies with more
severe patients with a mean MADRS of 30–31. No
subanalysis of the results in the severe patients has,
however, been published (Stahl et al., 2002). On these
data, it is concluded that venlafaxine has probable
superior efficacy compared with fluoxetine and other
conventional SSRIs in the treatment of severe depres-
sion. Clinical opinion holds firmly to the conclusion that
venlafaxine has superior efficacy compared with conven-
tional SSRIs in severe depression but this is not yet
properly documented in the published data.
The evidence that milnacipran may be superior in
treating severe depression depends on the subanalysis
of patients with severe depression in the meta-analysis
of the studies of Guelfi et al. (1998) in endogenous
depression and Clerc et al. (2001) in moderate and severe
depression, published by Lopez-Ibor et al. (1996). No
prospective study, however, exists in severe depression.
Milnacipran 100mg/day has possible superior efficacy in
severe depression.
The single study demonstrating the superiority of mirtaza-
pine was conducted in hospitalized patients with a minimum
score of 18 on the HAMD 17 (Van Moffaert et al., 1995). The
high mean baseline scores (HAMD 28–29) indicate that a
large proportion of patients were probably suffering from
severe depression. Unfortunately, there was no report of the
differential efficacy in moderate or severe subgroups and
there was no prospective definition of severe on a severity
scale so that the evidence from this single study is weakened
to a level where superiority can only be considered possible.
On the basis of these data, mirtazapine is considered to have
possible superiority.
Evidence of superior efficacy in severe depression is
found with escitalopram, which has positive results from
two individual studies that included only patients with
prospectively defined severe depression (defined as a
baseline score of at least 30 on the MADRS). Escitalo-
pram was superior to citalopram (Moore et al., 2005) and
paroxetine (Boulenger et al., 2006) on both primary and
secondary measures. In a subanalysis of patients with
severe depression in a single study, escitalopram was
significantly better than venlafaxine (Montgomery &
Andersen, 2006). In other subanalyses of data from
patients with severe depression in the meta-analysis of
comparator studies, the superiority of escitalopram was
also observed compared with citalopram (Lepola et al.,
2004; Llorca et al., 2005; Lam and Andersen, 2006) to
SSRIs and to all comparator antidepressants combined
(Kennedy et al., 2006). Class A evidence from two studies
allows the conclusion of definite superior efficacy but
only for the 20-mg dose of escitalopram. The evidence is
supported by superiority shown in several meta-analysis
in severe depression.
Conclusion on superiority in severe
depression
The available evidence supports the definite superior
efficacy in severe depression compared with comparator
antidepressants of escitalopram (two prospective studies
supported by meta-analyses), and probable superiority of
venlafaxine (one prospective study supported partially by
one meta-analysis) and possible superiority of milnacipran
(one study). Evidence of superiority of clomipramine is
based on two studies in hospitalized patients, in which
the severity was defined as moderate-to-severe rather
than severe alone without a published subanalysis, and
is therefore questionable but accepted as evidence
of possible superiority in the treatment of severe
depression.
Only escitalopram show definite superiority in the
treatment of severe depression. Venlafaxine has probable
superiority and milnacipran and clomipramine possible
superiority in the treatment of severe depression.
Overall conclusion
The criterion for definite superiority of an antidepressant
is based on results from two pivotal studies in moderate-
to-severe MDD, carried out under conditions of fair
comparison at approved doses of the antidepressants,
which demonstrate superiority on the primary efficacy
measure, or alternatively one pivotal study supported by
consistent results from meta-analyses. The criterion for
probable efficacy is based on consistent positive results
from meta-analyses of studies in patients suffering from
moderate or severe MDD. A review of the published data
finds evidence that some antidepressants are more
effective than others on the basis of these criteria. It
should be noted that conclusions for superiority are
generally dose-specific and may not hold true throughout
the approved dose range for the particular antidepressant.
Using these criteria, only three antidepressants are
considered to have definite superior efficacy — clomi-
pramine, venlafaxine, and escitalopram. Three anti-
depressants have probable superiority — milnacipran,
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duloxetine, and mirtazapine. Only escitalopram is con-
sidered to have evidence of definite superiority in the
treatment of severe depression with venlafaxine having
probable superiority.
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